Cancer patients get extended access to experimental drug
NCT ID NCT06987058
Summary
This study allows cancer patients who benefited from RVU120 treatment in previous trials to continue receiving the same therapy. It's for people with advanced solid tumors, acute myeloid leukemia, or high-risk myelodysplastic syndrome who are still responding well to the treatment. The main goals are to monitor safety and see how long patients can continue treatment while maintaining benefit.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinica Universidad de Navarra
Pamplona, 31008, Spain
Contact
-
Uniwersyteckie Centrum Kliniczne
Gdansk, 80-214, Poland
Contact
Conditions
Explore the condition pages connected to this study.